Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca and Merck & Co’s more established rival drug. Several po...
Original Article: Clovis hopes to get ahead of rivals in prostate cancer with Rubraca